Pharmafile Logo
Pharmafocus logo
Advanced Search
volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

FDA grants ODD to Revolo Biotherapeutics’ eosinophilic esophagitis treatment

February 1, 2024
Medical Communications FDA, ODD, Pharmacy, Revolo Biotherapeutics, eosinophilic esophagitis

Revolo Biotherapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ‘1104, …

News

MHRA approves GSK’s Omjjara in Great Britain for splenomegaly treatment

January 31, 2024
Medical Communications GSK, MHRA, Omjjara, Oncology, myelofibrosis, splenomegaly

GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Omjjara (momelotinib) in …

News
louis-reed-pwckf7l4-no-unsplash_5

Regeneron forms Regeneron Cell Medicines with acquisition of 2seventy bio

January 31, 2024
Business Services 2seventy bio, Pharmacy, Regeneron, Regeneron Cell Medicines, acquisition

Regeneron Pharmaceuticals has announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio to acquire the …

News

FDA clears IND for Gracell Biotechnologies’ phase 1 clinical trial for multiple myeloma treatment

January 30, 2024
Research and Development FDA, Gracell Biotechnologies, Oncology, clinical trial, multiple myeloma

Gracell Biotechnologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, …

News

Oxford Biomedica acquires ABL Europe for €15m

January 30, 2024
Business Services ABL Europe, Oxford BioMedica, Pharmacy, acquisition

Oxford Biomedica has announced that it has completed the acquisition of ABL Europe from Institut Mérieux. This follows announcements on …

News

EMA to review GSK’s Arexvy for RSV prevention in adults aged 50-59

January 29, 2024
Medical Communications Arexvy, EMA, Infections and infestations, RSV

GSK has announced that the European Medicines Agency (EMA) has accepted the company’s regulatory application to expand the use of …

News

Vergent Bioscience shares phase 2 data for VGT-309

January 29, 2024
Research and Development Oncology, VGT-309, Vergent Bioscience, lung cancer

Vergent Bioscience has announced new data from a phase 2 trial of VGT-309, the company’s investigational tumour-targeted fluorescent imaging agent. …

News

MHRA approves Mounjaro for diabetes and weight management

January 26, 2024
Medical Communications Diabetes, MHRA, Mounjaro, weight management

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it has approved a four-dose version of the diabetes …

News

AbbVie invests $223m in Singapore manufacturing site

January 26, 2024
Manufacturing and Production AbbVie, Pharmacy, Singapore, manufacturing

AbbVie has announced that it has invested $223m in an expansion to its Singapore manufacturing facility. This will create more …

News

Haleon recalls cough syrups due to microbial contamination

January 25, 2024
Medical Communications Haleon, Pharmacy, cough syrup, microbial contamination

The US Food and Drug Administration (FDA) has shared an announcement from Haleon detailing the voluntary recall of eight lots …

News

Alphamab Oncology and 3DMedicines enter licensing agreement with Glenmark Speciality

January 25, 2024
Medical Communications 3DMedicines, Alphamab Oncology, Glenmark Speciality, Oncology, envafolimab

Alphamb Oncology and 3DMedicines have announced that they have entered into a license agreement with Glenmark Speciality, a subsidiary of …

News

Futura Medical appoints Roy Davis as non-executive director

January 25, 2024
Business Services Futura Medical, Roy Davis, appointment, non-executive director

Futura Medical has announced the appointment of Roy Davis as non-executive director effective immediately. Roy has extensive commercial experience in …

Appointment

Cellular Origins appoints Peter Crossley as chief operating officer

January 25, 2024
Business Services Cellular Origins, Peter Crossley, appointment, chief operating officer

Cellular Origins, a TTP Company, has announced that it has appointed Peter Crossley as chief operating officer (COO). Peter brings …

Appointment

BenevolentAI appoints Dr Joerg Moeller as CEO

January 25, 2024
Business Services BenevolentAI, CEO, Dr Joerg Moeller, appointment

BenevolentAI has announced that it has appointed Dr Joerg Moeller MD PhD as chief executive officer and executive board member …

Appointment

Onward Therapeutics announces enrolment of phase 1 trial of bispecific antibody

January 24, 2024
Research and Development Oncology, Onward Therapeutics, bispecific antibody, clinical trial

Onward Therapeutics has announced that it has begun enrolment for its phase 1 clinical trial of OT-A201, a novel bispecific …

News

InnoCare announces first patient dosed in zurletrectinib clinical trial in China

January 24, 2024
Research and Development InnoCare, Oncology, clinical trial, zurletrectinib

InnoCare Pharma has announced that the first paediatric patient has been dosed in a clinical trial of the company’s second …

News

CN Bio and Altis Biosystems partner for development of in vitro model for ADME studies

January 23, 2024
Research and Development ADME studies, Altis Biosystems, CN Bio, Pharmacy

CN Bio and Altis Biosystems have announced that they will enter a strategic partnership, through which Altis’ human RepliGut Planar-Jejunum …

News

Sanofi to acquire Inhibrx for approximately $1.7bn

January 23, 2024
Business Services Inhibrx, Rare Diseases, Sanofi, acquisition

Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for Sanofi to acquire Inhibrx following …

News

UKHSA warns of measles outbreak

January 22, 2024
Medical Communications Infections and infestations, MMR, UKHSA, measles, vaccination

The UK Health Security Agency (UKHSA) has warned that further outbreaks of measles could spread to other towns and cities …

News

FDA approves Balversa for bladder cancer treatment

January 22, 2024
Medical Communications Balversa, FDA, Johnson & Johnson, Oncology, bladder cancer

Johnson & Johnson (J&J) have announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug …

News

Latest content

OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

May 24, 2024

Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies

May 24, 2024

BioGen to acquire Human Immunology Biosciences for $1.15bn

May 23, 2024

Merck to acquire Mirus Bio for $600m

May 23, 2024

Rare disease clinical trials: the urgent need for patients to be heard

May 22, 2024